Thursday, October 3, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil ...

Muscle-sparing is particularly important in patients with heart failure as it is associated with higher mortality.

US researchers have found that obesity or being overweight is linked to a life-threatening heart condition that alters muscle structure in the organ ... Mounjaro And Zepbound Can Reduce Risks Of Heart ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

BTC's implied volatility curve shows a noticeable kink on Oct. 5, signaling expectations for an unusually volatile Saturday.

By Dani Blum The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been resolved. Tirzepatide, the active ingredient in the diabetes and ...

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly’s Mounjaro was added to the FDA’s drug shortage database in 2022, while Zepbound was added this April. Eli Lilly did not immediately respond to a request for comment from Quartz.